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T he fundamental concept in pathogen reduction technology (PRT) is the ability to inactivate pathogens and thus reduce the risk of transfusiontransmitted infections while maintaining the integrity of constituent blood cells. The main consideration in PRT is not only the maximum killing capacity but also how PRT performs in relation to the levels of infectious agents that can be expected in asymptomatic individuals who could pass the donor medical screening process. In this review we summarize the circulating levels of infectious agents and the likelihood of infectivity from these levels. This is put in context with other factors that influence the likelihood of infections from a particular blood product.
VIRAL QUANTITATION AND TERMINOLOGY
Evaluation of PRT technologies is difficult because of the use of multiple terms for the quantitation of pathogen levels in donors and in the PRT product. Units used include international units (IU), genome equivalent (geq), copies, AND virions. For other agents such as Plasmodium or Babesia, the number of parasitized cells is described.
International units
IUs are usually established under the aegis of the World Health Organization involve testing multiple samples containing the agent of interest in multiple laboratories. Based on these results, one of the samples is selected as the standard and an IU is based on that material and the testing results. For instance, the first IU for hepatitis C virus (HCV) RNA was established by testing three candidate materials in 22 different laboratories. 1 The samples had approximately 10 5 genome equivalents (geq)/mL. The candidate sample selected as the standard was assigned a titer of 10 5 IU/mL and thus 1 IU equaled 5 geq. Because an IU relates to a specific sample for a specific agent, an IU does not mean the same level of activity for different agents. IU have been established for some but not all. Infectious agents and thus some reports use IU, while others use other measures.
Genome equivalents
Nucleic acid amplification testing (NAT) identifies a nucleic acid sequence thought to occur only once within the agent being tested. However, the "clinical sensitivity of NAT methods can be improved by dual region detection or addition of redundant oligonucleotides to avoid detection of genetic variants of viruses." 2 This confounds the quantitative nature of these tests, making it difficult to determine whether each reaction detects a single virus. NAT does not provide information about the nonidentified remainder of the genome. It is possible that portions of the genome may be damaged or incomplete. Thus, the number of genomes identified by NAT does not necessarily relate to the number of infectious organisms.
Virus copies
The term viral copy is used loosely to be the same as geq except that as mentioned above, the geq assumes that the quantitative NAT identifies individual viruses and the complete genome is intact, which might not be the case. Thus, it may not be appropriate to equate geq to a complete infectious viral copy. equivalent to 5.33 copies of hepatitis B virus (HBV), 2.73 copies of HCV, and 0.58 copies of HIV, but does not explain the basis of these conversion factors. Kleinman et al., 4 assume three to four copies of HCV per IU but do not reference the source of this conversion. Allain et al. 5 used a conversion of five copies of HBV to 1 IU/mL. Busch et al. 6 seem to use copies/mL and geq/mL interchangeably. Some divide the number of HIV copies/mL in half to get HIV virions; others extrapolate 180 IU of HBV DNA to approximately 900 copies/mL with no indication for the basis of this extrapolation or the source of this conversion factor. 4 The use of different units illustrates the difficulty of aggregating or comparing data to develop any generalizable concepts of the levels of infectious agents affected by PRT.
DETERMINATION OF KILLING CAPACITY OF PRT TECHNOLOGIES
Kleinman al. 4 summarized the methods for studying infectivity of transfusions as 1) in vitro cell culture, 2) animal models, 3) isolated case investigation, 4) systematic studies using frozen donor/recipient repository specimens, and 5) systematic look-back studies. Those authors 4 point out the advantages and disadvantages of each. The uncertainties complicating the interpretation of human transmission cases include 1) limitations of quantifying viral load at low viral concentrations, 2) lack of standardization of NAT assays, 3) unknown plasma volume of transfused component, 4) possible effect of intracellular virus or cell-bound virus not captured by quantitative NAT assays, 5) unknown effect of storage time and temperature on the blood component, and 6) missing essential data. Thus, "no single level of virus reduction can fully describe the requirements for and performance limits needed to define efficacy for PRT." 4 PRT is "unlikely to sterilize the transfusion product" because of 1) large pathogen loads, 2) resistant forms of infectious agents, 3) inaccessible pathogens due to bag geometry, 4) poor light energy delivery due to interfering substances, or 5) potential human error. 7 An in vitro killing capacity of 10 6 is often mentioned as an objective for PRT. However, this figure was established for the pharmaceutical industry 8 and was based on the level of contaminating bacteria that might be introduced during manufacturing in nonsterile environments. 8, 9 While 10 6 has been applied to blood products, this was not derived for microbes that might be circulating in apparently healthy blood donors and might make their way into traditional blood products. The issue is further complicated by attempts to extrapolate these in vitro results into prevention of infectivity. Because PRT may alter microbial infectivity while maintaining some ability to detect genome equivalents, the results cannot be directly translated into the number of organisms that are likely to be inactivated in donated blood. An additional difficulty in attempting to project inactivation numbers into infection prevention is that for most of the killing studies, the genome mutations and ratio of nucleic acid equivalents in relation to infectivity are not known. The ultimate data regarding the effectiveness of a PRT method will probably be the transmission of disease. 10 The use of a specific kill level is not clinically meaningful.
FACTORS THAT INFLUENCE TRANSMISSION OF INFECTION
Kleinman et al. 4 indicate that "there is variability across recipients in whether infection occurs as result of transfusion of a blood component with a given nucleic acid concentration." 4 The likelihood of infection from a particular unit of blood is related to 1) the virus/infectious agent, 2) the blood component being transfused, and 3) the patient (Table 1) . Those characteristics attributed to the virus itself and thus the most pertinent to PRT are the 1) viral load, 2) viral genotype, 3) genome mutations, 4) ratio of detectable nucleic acid equivalents to infectious particles, 5) stage of viral infection in the donor, 6) binding of the virus to endogenous neutralizing antibodies, and 7) viral replication capacity. The reasons for failure to transmit infection include 1) low viral load, 2) subinfective volume of blood transfused, 3) loss of viral infectivity during storage of the component, 4) recipient resistance due to clinical or genetic factors, 11 5) partial neutralization by donor antibodies, and 6) loss of viability of stored lymphocytes.
Viral load
Viral load is the key factor in transfusion-transmitted infection. However, infectivity may differ considerably before (window period) and after the immune response if free particles are more infectious than those complexed to antibody. In addition, each viral particle is infectious independently of other virus particles. 12 The infectivity of a genome is not necessarily known because PRT may alter microbial infectivity while maintaining some ability to detect nucleic acid sequences. For instance, in inactivation processes of plasma derivatives, NAT levels do not parallel HIV infectivity. 13 "The presence of a virus particle or portion of a virus particle … does not necessarily correspond directly to the presence of an infectious viral particle … The viral copy number obtained by NAT may include replication incompetent DNA fragments and therefore not directly relate to infectivity." 9 The frequency of replication-competent virus varies widely with the type of virus and stage of infection but may be only a small fraction of circulating genome equivalents. For instance, blood with similar viral loads may or may not transmit infection. 14 Infection from 10 3.6 copies/mL but not from 10 3 copies of West Nile virus (WNV) 15 illustrates that factors other than viral load are involved.
The blood component
The particular component can influence infectivity due to the volume of plasma that then determines the total infectious load being transfused. For instance, Allain et al. 5 reported HBV infectivity rates of 31%, 50%, and 84% for RBCs, platelets, and plasma, respectively. There has been transmission from one but not a different component from the same donation. 16 While the viral load was not reported, the authors suggest that differential infectivity might be due to the total viral load transfused (higher in platelets due to plasma volume). Hepatitis E virus (HEV) transmission rates of 25% from RBCs and 100% from fresh frozen plasma have been reported. 17 
Storage age of RBCs
The storage age of RBCs also is a statistically significant factor in the likelihood of infection transmission. Donegan et al. 18 observed that HIV infectivity was significantly higher from RBCs stored 8 days or less. Busch et al. 19 reported 93%
infectivity from RBCs stored less than 25 days compared with 50% from RBCs stored more than 25 days. Infectivity has been "reduced due to virus degradation upon refrigerated storage of RBC components for more than 7 days at 4 º C." 4 Weusten et al. 20 cite various data suggesting that "in stored RBCs, the infectivity of HIV may be logarithmically reduced." This storage effect on infectivity might be related to a loss of lymphocyte viability during storage or decreased infectivity of virus particles. 18, 19 Genetic variation of the infecting agent During the eclipse phase of HIV infection, there may be no detectable plasma viremia 4, 24 and possibly not enough virus to be infectious. Following eclipse, is the pre-ramp-up phase (window) in which viral proliferation is slow, followed by the ramp-up phase with exponential virus expansion and infectivity and occurrence of symptoms. 21 Because peak viremia often corresponds to the symptomatic phase of acute infection, these individuals usually would not pass the blood donor medical assessment. However, high viral loads may be present in asymptomatic individuals such that donor exclusion based on clinical symptoms is important, but not enough to exclude all highly infectious donors.
The recipient
Underlying patient "susceptibility factors such as genetics, age, immune activation or immunosuppressive treatment may influence the relationship of viral load to infectivity." 4 Factors in the patient/recipient that can influence infection transmission include existing immunity such as neutralizing antibodies from previous infection, lack of viral receptors, the degree of immunosuppression, the recipient's blood volume, or maternal antibodies in neonates ( Table 1 ). The host innate immune response provides an opportunity to affect or abort the infection and thus impact the importance of the level of viruses or other infectious agents in the donor.
CIRCULATING LEVELS AND INFECTIVITY OF HIV, HBV, AND HCV HIV

Circulating levels
In a study of sera from plasma donors, Feibig et al. 25 defined six stages of infection with plasma RNA levels ranging from 10 2 to 8 copies/mL. NAT-negative window period donors have been reported 20, 26 with viral levels of 82 -3 × 10 7 and NAT-positive donors with less than1600 to as high as 10 8 copies/mL ( 
Infectivity
Busch et al. 31 hypothesized that one viral copy per 20 mL would be infectious. While transmission from HIV NAT-positive blood is thought to be very likely, occasionally infection is not observed. 11 For instance, in one report, 9 of 10 recipients became infected from HIV-positive blood components in which the viral load varied from 5 to 246 copies per Ml 4 ; thus, while there was a 90% infectivity rate, "positive blood components from donors in the eclipse or early window phase are not always infectious." 4 A 50% infection rate has been estimated from 400 virions ( Table 2) . 4 Transmission of HIV has occurred from levels as low as five copies or 3.7 IU/mL or 20 copies/mL to 10 3.6 or 7.5 IU (Table 3 ) and up to 10 3.6 copies/mL, but lack of transmission of HIV has been demonstrated from units with 10 3 copies ( Table 2 ).
Some donors in the chronic phase of HIV infection also do not transmit HIV. Plasma from chronic-phase infections may require 75-fold higher than window-phase concentrations to be infectious. 4 This is illustrated by the absence of infection after receipt of 10 4 to 10 6 copies from chronicphase infected donors (Table 2 ) versus infectivity at much lower copy levels from donors in the acute window phase of infection ( Table 2 ). This effect may be due to neutralizing antibodies in the donor. This is similar to chimp data suggesting that chronic phase plasma may be one hundredfold less infectious than acute-phase plasma 4 and is very much less infectious than when detected at similar concentrations during the acute phase ramp-up viremia. 4 
Hepatitis B virus Circulating levels
Window-phase donors ( Fig. 1 ) have been reported with HBV levels ranging from 1 to 1460 IU/mL or 2400 copies/mL (Table 3 ). In the pre-ramp-up phase, there is low-level HBV DNA detectable intermittently and only with high-sensitivity individual donor (ID) NAT. 32, 33 There is poor correlation between HBsAg and DNA, and generally DNA levels are highest before the appearance of HBsAg and markedly lower once HBsAg and antibody to hepatitis B core antigen (anti-HBc) are present together at the time of seroconversion (Table 3 and Fig. 1 ). 34, 40 The relationship of virus levels to NAT is illustrated in a French study of 203 blood donors (Table 3) . 38 Mini-pool (MP) NAT-positive, ID-positive donors had 17,000 copies/mL; MP-negative, ID-positive donors had 1470 copies/mL; and MPnegative, ID-negative donors had 200 copies/mL. During HBV infection, after the window period, rampup phases, and occurrence of symptoms (Fig. 1) , patients may enter an asymptomatic phase in which they are viral carriers for years to decades. The declining viremia in chronic infection is probably explained by the formation of immune complexes of viral particles and neutralizing antibodies. This logically would provide lower infection rates per viral particle, although there are sparse data to confirm this. During the immune clearance phase of chronic infection (Fig. 1) , DNA is generally present in concentrations of less than 100 IU/mL (Table 3 ) and can fluctuate between being detectable or undetectable. Some chronic carriers are HBV-DNA positive, anti-HBc positive, but HBsAg negative in what has been termed occult hepatitis B infection (OBI) and is usually related to mutations in the HBsAg coding region of HBV DNA. Such OBI donors have been reported with approximately 20,000 to 90,000 copies/mL, 4, 41, 42 but there are no data as to whether units from these donors are infectious. 4 In some cases of OBI there is a very low but sometimes detectable HBsAg level and a surface antigen-to-HBV-particle ratio of-10 to 1, which is attributed to antigenic variants. 4 During chronic HBV infection, there is a prolonged inactive carrier state ( Fig. 1 ) with low-level viremia and poor correlation between HBsAg and DNA. DNA levels in HBsAgpositive anti-HBc-positive donors are "extremely" low-as low as 1.3 copies/mL (Table 3) 34 and could be missed by NAT screening. It is here that anti-HBc testing is most valuable in detecting silent HBV carriers. In this stage of HBV infection, PRT would be most efficacious.
Infectivity
The level of virus may differ very little between infectious and non-infectious blood (Table 4 ). In 17 samples of anti-HBsnegative products, the viral load transfused was 1500 (180-56,000) copies/mL in nine patients who became infected and 900 (200-19,800) copies/mL to eight noninfected patients. 5 In separate calculations, Allain et al. 5 report a geometric mean of 1032 copies/mL for those not infected and 2694 copies/mL for those infected (p = 0.003). In the Weusten et al. 43 model of chronic infection, 3.3% of all donations not detected by ID NAT (and thus possibly prevented by PRT) would cause infection, and if a six-donor MP NAT were used, the infection rate would increase to 8.7%. In a separate report, 2 of 11 (18%) recipients became infected from viral loads of 50 to 500 copies. 43 Donors are suspected of transmitting HBV with 50 to 620,000 geq/mL; but four transmitting donors had very low levels of less than 50, 400, 500, and 800 geq. 44 The minimum copy number of HBV DNA in chronic carriers that can infect chimps is estimated as 3 to 169 geq/mL. 45 From hemovigilance activities Satake et al. 14 observed that 12 of 63 patients acquired HBV as a result of the transfusion of ID NAT only positive components and many of the infectious levels were below pooled NAT detection levels. The authors conclude that this represents a 19% infectivity rate. If patients who were not known to be HBV negative before transfusion are excluded, the infectivity rate would be 27%. A plasma donor with fewer than 200 copies/mL of HBV transmitted hepatitis, although the stage of infection in the donor is not reported. There was lack of infection from 1200 to 1500 copies from window-phase donors and the 50% infectious dose was estimated as 400 virions. 4 Weusten et al. 43 calculated that about 50% of anti-HBs nonreactive donors (< 10 IU/mL) can be expected to be infectious. Anti-HBc = antibody to hepatitis B core antigen; ID = individual donor; IU = international units; MP = mini-pool; NR = not reported.
The presence of anti-HBc is a factor in infectivity. Infectious anti-HBc-negative units had 100 to 7300 copies/mL, but those that did not transmit infection had similar virus levels (100, 172, and 3300). 19 They attribute this to immune factors or that viral copy numbers may include replication incompetent DNA or DNA fragments that do not relate to infectivity. The rate of hepatitis transmission from donors with low copy numbers of HBV (<100/mL) that were antiHBc negative was 50% versus 3% in those who had antiHBc. 4, 15 Low anti-HBc titer units are infectious at 2.4% to 3%, whereas anti-HBc-negative components are infectious at a rate of 37% to 50%. This illustrates that transmission of HBV window-period components is more than 10-fold higher than transmission by chronic carriers. Tabuchi et al. 46 projected a 100-fold higher infectivity between preacute phase serum than late phase blood. In comparing two test systems, Grabarczyk et al. 3 identified
an anti-HBs-negative donor with 9 to 37 copies/mL, which they project statistically would have had a 50% to100% likelihood of transmitting infection from RBCs or fresh frozen plasma, respectively. Of 11 recipients in Taiwan who received transfusions from HBV DNA-positive donors with 50 to 500 copies/ mL, 47 only one developed HBV infection and that recipient received blood with 500 copies/mL. This low level of infectivity might be due to a relative lack of infectivity of units from donors in the inactive carrier phase of HBV infection. 4 Infection from some units of fresh frozen plasma has occurred with less than 100 copies, but other units with 100, 120, 93, and 98 copies were not infectious, 14 and Prince et al. 48 found no transmission from donors with 200 to 1300 copies/mL.
Hepatitis C virus Circulating levels
Virus levels are low in early onset of HCV infection ranging from <1 geq/mL to 15,000 geq/mL ( Table 5 ). The period of high viremia (estimated as 50 days) has a rapid development of positive NAT and rapid doubling time of virus with copies ranging from 10 5 to 10 7 (Table 5) . 6 Carriers with viral loads below detectability have been reported. 27 
Infectivity
During the pre-seroconversion phase, infection can be transmitted by as few as 10 to 100 geq/mL. 6 High rates (95%-100%) of transmission occurred from viral levels of 101 to more than 100,000 copies/mL, although 1 of 12 recipients was not infected by NAT-negative blood. 52 While 98% of patients who received HCV-seropositive units with greater than 100 copies of HCV/mL became infected, "it is not possible to make firm conclusions about the frequency of HCV transmission when units with fewer than 100 HCD copies/mL are infused in the presence of HCV antibody." 4 The few cases of HCV transmitted by NAT-negative donors had very low viral loads. In one study, 4 20 copies of HCV/mL were infectious and 2 copies/mL were not. This is extrapolated to a 50% infectious dose of 7 to 20 RNA copies/mL, 4 which is well within the killing capacity of PRT. HCV has been transmitted to chimps at loads of 4 to 100 copies/mL per animal. 4 This assumes 3 to 4 copies/IU but the reason for this assumption is not provided.
Summary of infectivity in relation to in vitro results
According to Kleinman et al., 4 "there may not be a single minimal infectious dose for all types of recipients." 4 Transmission of HIV, HBV, and HCV can occur from units with levels fewer than 100 copies of HBV or HCV (not detectable by NAT); even 1 geq/mL of plasma can cause infection if sufficient volume is transfused, and this level is well below the limit of detection of individual NAT. 4, 29 Weusten et al. 21 calculate that the chances of infection from one unit of RBCs from a donor in the window phase (20 mL of plasma containing 20 virions) are21.7% for HIV,18.7% for HBV, and8.6% for HCV. There are several examples of the lack of correlation between in vitro killing capacity and prevention of infection. One example is malaria. Keil et al. 30 showed a 10 3.2 reduction in infectivity of malaria in vitro, but Allain et al. 54 found an 87% reduction in transmission of malaria from transfusion of PRT whole blood from donors with 10 4 to 10 6 parasites/mL.
Zika is another example of the lack of correlation between in vitro killing reports and infectivity. Virus levels were 10.25 copies/mL before and 9.51 copies/mL after pathogen inactivation using the amotosalen ultraviolet A method, but these posttreatment samples were not infectious in vitro, 55 indicating that whatever is being measured after inactivation does not correlate with infectivity. Even more striking is the low level of infectivity (4%) of semen samples 
OTHER VIRUSES Cytomegalovirus
Detection of CMV DNA and prediction of infectivity have been problematic for years. Studies of CMV NAT testing of healthy donors may vary considerably depending on the presence of anti-CMV. There is no agreement on levels and time of occurrence of CMV DNA. Some infected individuals can have CMV DNA before development of antibody, but such window-phase donors appear to be rare. The DNA copy number has not been correlated with infectivity and the minimal CMV DNA load necessary for infection is not known.
59
CMV DNA is often reported in relation to the number of WBCs because that is where the virus is thought to reside. The distribution of virus between cells and plasma is not known but probably differs at different stages of infection. Another complicating factor in interpreting results of CMV DNA is that some reports are of DNA/WBCs and others of DNA/peripheral blood mononuclear cells.
Greenlee et al. 60 found no copies of DNA in about 100 CMV antibody-positive donors and Roback et al. 61 found CMV DNA in only 4 of 48 cord blood units with anti-CMV. Viral loads in 3 of the 4 were 651, 54,000 and 568,699 copies/ mL. In an earlier study Roback et al., 59 found CMV DNA in only 2 of 1000 samples and levels were estimated as 10-99 geq per 250,000 WBCs. Neither donor had detectable plasma DNA. Ziemann et al., 62 found CMV DNA viral loads of mean 166 and maximum of 3200 geq/mL in 36 of 83 newly seropositive donors. In a separate report, Ziemann et al. 63 found viral loads in whole blood and plasma for window period Anti-HBc = antibody to hepatitis B core antigen; geq = genome equivalent; IU = international units; NAT = nucleic acid amplification testing; NR = not reported.
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infection from median of 400 IU/mL (range, 300-500), early seropositive 500 (range, <300-4000), and latent phase 30 (range, <300-800) IU/mL. Levels in plasma ranged from <12-700 IU/mL. Transmission of CMV infection was not found after transfusion of less than 371 IU/mL. 64 Thus, in aggregate, reports show a variety of data difficult to summarize. Some reports are in IU, 63, 64 some in geq, 62 some in copies/mL 60, 61 and some related to WBCs and some in plasma or whole blood.
West Nile virus
In experimental infection, virus becomes detectable 1-2 days after inoculation 65 but the timing of this in wildtype infection is not known because of the difficulty in determining the actual time of infection. Not surprisingly, viral levels vary with the stage of the West Nile infection. 66 Once viremia is detectable by sensitive ID NAT, there is a period of about 1 to 2 days before adequate virus levels for detection by MP NAT. 65 RNA peaks at 10 5 geq/mL about 5 days after infection. 16 Ten subjects followed over time had a mean value of 343 copies/mL, 66 maximum levels were all less than 1000/mL. Transfusion transmission can occur during this phase. Viral loads are about 5 × 10 3 copies during MP NAT-positive but antibody-negative phase and then drop to less than 50 to 100 copies/mL once IgM antibody appears. 16 Viremia can continue for 13 to up to 40 days while antibody develops, but units "positive for WNV specific antibody are not infectious." 16 "Although most donors clear the virus in weeks, low levels of virus may persist for several months after sero-conversion eventually dipping below the level of detectability by ID NAT." 65 WNV is less infectious once individuals have developed antibodies compared to earlier in the course of infection before antibody development. 4 Lanciotto et al. 67 suggest that a mean 10 5 (range 10 4. 45-6.29 ) reduction is adequate to close the window for WNV transmission. After seroconversion, the value of screening whole blood for RNA is limited 66 because there is very little or no transfusion transmission. 4, 16, 66 This is illustrated by Rios et al., 65 who report 32 cases of WNV transmission, all of which had low plasma RNA load. They used in vitro culture to evaluate the infectivity of WNV RNA containing blood. The presence of WNV antibody affected infectivity, with 74% of antibody-negative and 36% of antibody-positive sera being infectious. In antibody-negative samples, 82% had high viral load compared with 50% high viral load in antibody-positive samples. Infectivity was similar for antibody-negative low or high viral loads: 85% and 80%, respectively. Of antibody-positive samples, infectivity was higher in samples with high compared with low viral loads: 42% versus 29%. Thus, WNV RNA-positive sera remain infectious despite the presence of antibody, even if levels of RNA are low. Antibody-positive plasma may be a less effective transmitter, but in vitro culture studies establish that the presence of antibody did not prevent infection. MP NAT fails to detect 25% of infected units of blood with low viral loads, and most of these are antibody positive and thus would not be expected to be highly infectious.
Hepatitis E virus
Fifteen of 25,000 Danish donors had low levels of virus in the early seronegative phase, with a median of 13 IU/mL and a range from unquantifiable to 920 IU/mL. 68 Only 1 of 15 recipients of these units appeared to become infected, and this was from a total dose of 1930 IU of virus. 68 In HEV infection, viral levels are 10 times higher in patients with acute hepatitis compared with chronically viremic donors. 18 Apparently, the body can rapidly clear about 10 11 virions per day because of innate immunity, which helps reduce the infectivity of blood, especially with low-level viremia. Thus, it appears that during symptomatic infection, levels may be quite high, but then virus persists only at low levels in asymptomatic individuals. found an 87% reduction in transmission of malaria in 65 patients who received PRT whole blood, including prevention from 12 of 13 donors with greater than 10 7 levels of parasitemia.
Zika virus
Malaria parasites go through life cycle stages, and infectivity may depend on the life cycle stage in addition to the level of circulating parasites. Because malaria parasites are associated with RBCs, the infectivity of platelets or plasma is probably different from the infectivity of RBCs.
Babesia
In babesiosis, parasites may be intracellular (RBC) or free in the plasma, and parasites in both locations are infectious. This makes it more difficult to define the level of parasitemia that correlates with infectivity. In one study, 95 96 The median parasite load in the 15 windowperiod donors was 350 parasites/mL. In NAT-and antibodypositive donors, the median load was 366 parasites/mL and maximum parasite load was 2,990,624 parasites/mL compared with a range of 14 to 11,020/mL in those who were antibody negative. The relationship of these units of blood and the parasite loads to infectivity were not reported because this was a donor screening study not structured to identify recipients of these units.
Patients have been reported with 450 to 4,800,000 parasites/mL, 97 but these patients were clinically ill and would not present as blood donors. Thus, the level of Babesia parasites that is infectious is not known, but it appears that circulating parasite loads range from 5 to 2,990,624. In a hamster model, the riboflavin ultraviolet light pathogen reduction system prevented transmission from plasma loads of 10 4 to 10 5 /mL, 98 a pathogen load in the range that might occur in an asymptomatic carrier.
Trypanosoma cruzi
Infection with the parasite T. cruzi involves an initial acute phase of high parasitemia and symptoms, although these are often mild such that these individuals might pass the blood donor screening process. 99 Following the acute phase, parasites decrease, and during the long latent phase are located in tissues, especially muscle, but usually not in the circulation. 100 Asymptomatic women can transmit the infection to their infants 10% of the time. 101 In RBCs, parasite levels are very low, at about one parasite/50 mL of blood, 9 and thus PRT should be quite effective.
To evaluate the inactivation capacity of NAT, Cardo et al. 102 used a culture system to demonstrate a 10 5-7 reduction of T. cruzi in plasma and 10 7-8 reduction in platelets when using the riboflavin ultraviolet system. While little is known about the range of circulating parasites in carriers, the risk of transmission is estimated at 13% to 23% for each unit of infected blood transfused. 103 Thus, it can be estimated that a 10 5-8 reduction in parasites should lead to a substantial reduction in infections.
CONCLUSIONS
Data on the levels of agents that could be expected in apparently healthy individuals who present as blood donors are limited. Even the same circulating level may have different infectivity at different stages of infection in the donor. Measurement of viral levels is not consistent, and the most frequently used approach (e.g., genomic equivalents) may not reflect infectivity. This is further complicated by infectious agents having widely variable properties. Several factors determine whether a particular unit of blood will transmit infection, and only one of these is the circulating level of infectious agent. Further, for many viruses or parasites, the circulating levels or infectivity are not known. Therefore, it is not feasible to draw any conclusions about the level of inactivation necessary to prevent infection. Studies of PRT potential have used different methods, and therefore it is not possible to draw conclusions regarding the inactivation capacity of different technologies against different agents. Pathogen inactivation capacity in vitro sometimes does not coincide with infection prevention in animals. The only clinical trial 54 that has established the clinical value of PRT for reduction of infection transmission did not correlate with laboratory evidence of Plasmodium inactivation. Testing strategies using NAT and enzyme-linked immunosorbent assay methods are effective in detecting blood containing high levels of infectious agents, but some infections can be transmitted by test-negative blood. Thus, an important value of PRT is for low levels of infectious agents that are missed by the current testing and other mitigation methods. Considering PRT only in terms of the strength of pathogen killing is overly simple and perhaps not clinically relevant. Other components of current blood safety strategies, particularly NAT, will continue to be used for the major infectious threats, and PRT will serve best as an additional blood safety layer. PRT will be valuable for virtually all infectious agents, by eradicating low-titer but infectious agents undetected by NAT, by possibly eliminating serologic assays, by eliminating the need for irradiation and leukoreduction, and by being a potent means to kill bacterial contaminants in stored platelets. PRT may not be the magic bullet once envisioned but will be a major advance in blood safety and our best strategy to preempt the next lethal blood-transmitted epidemic.
